Ferrucci P F, Vanazzi A, Crosta C, Pruneri G, Grana C, Bartolomei M, Paganelli G, Martinelli G
Hematoncology Division, European Institute of Oncology, Via Ripamonti 435, 20100 Milan, Italy.
Ecancermedicalscience. 2008;2:79. doi: 10.3332/eCMS.2008.79. Epub 2008 Mar 13.
Treatment modalities for resistant/relapsing gastric mucosa associated lymphoid tissue (MALT) non-Hodgkin's lymphoma (NHL) are not yet well standardized. In the past, most patients were treated surgically with a gastrectomy, while, more recently, radiotherapy and systemic approaches (chemotherapy and immunotherapy) have been used with improving results.Here, we report the case of a patient affected by MALT NHL resistant to antibiotics, chemotherapy and immunotherapy, who achieved a durable complete remission after radio-immunotherapy treatment with Zevalin ((90)Y ibritumomab-tiuxetan), administered in a single-standard dose. This observation must be confirmed on a larger series but suggests that radio-immunotherapy may be a valid approach in treating relapsing MALT NHL patients, or those resistant to conventional therapies, so avoiding more aggressive and toxic approaches.
难治性/复发性胃黏膜相关淋巴组织（MALT）非霍奇金淋巴瘤（NHL）的治疗方式尚未得到很好的标准化。过去，大多数患者接受胃切除术进行手术治疗，而最近，放疗和全身治疗方法（化疗和免疫治疗）的使用取得了更好的效果。在此，我们报告一例受MALT NHL影响的患者，该患者对抗生素、化疗和免疫治疗均耐药，在接受单标准剂量的泽凡（（90）钇伊布妥昔单抗）放射免疫治疗后实现了持久的完全缓解。这一观察结果必须在更大的系列研究中得到证实，但表明放射免疫治疗可能是治疗复发性MALT NHL患者或对传统疗法耐药患者的有效方法，从而避免采用更激进和有毒性的方法。
